lymphangiogenic growth factors, cytokines and proteases intended for tissue repair, but they promote tumor progression directly, or indirectly through angiogenesis induced by vascular endothelial growth factor (VEGF). 6, [8] [9] [10] [11] [12] [13] In fact, macrophages are known to influence the poor prognosis in PDAC patients. 5, 14 However, the role of showed significantly poorer prognosis than those harboring PD-L1-negative tumor cells. 15, 16 In addition, PD-L1 expression in cancer cells has been reported to be correlated with the number of TAM in hepatocellular carcinoma and gastric cancer. 17, 18 Although these results suggest that infiltrating immune cells affect PD-L1 expression level in PDAC cells, the correlation has not been clearly elucidated.
Therefore, this study was conducted to elucidate the molecular mechanism underlying PD-L1 expression mediated by infiltrating immune cells in PDAC.
| MATERIAL SANDME THODS

| Patients
From January 2004 to December 2014, a total of 252 patients underwent surgical resection with curative intent for pancreatic cancer at Kumamoto University Hospital and Kumamoto Regional Medical
Center in Kumamoto, Japan. After excluding 17 patients whose data
were not fully available, 235 patients were eligible for this study. In addition, we collected 6 frozen pancreatic cancer tissues resected 
| Immunohistochemistryanalysis
Deparaffinized formalin-fixed paraffin-embedded (FFPE) consecutive tissue sections were prepared for heat-induced antigen retrieval in citrate or EDTA solution. For immunostaining, we used an indirect method with a monoclonal mouse anti-CD163 primary antibody (10D6;
Leica, Newcastle, UK) or polyclonal rabbit anti-CD8 primary antibody (ab4055; Abcam, Tokyo, Japan) or an avidin-biotin complex method with a monoclonal rabbit anti-PD-L1 primary antibody (#13684; CST, Tokyo, Japan) and an anti-mouse or anti-rabbit IgG antibody conjugated to HRP (Dako, Tokyo, Japan) as the secondary antibody. Mouse or rabbit IgG was used as the negative control. Immunostaining evaluations were conducted by 2 pathologists blinded to the sample identity.
CD163-positive cells and CD8-positive cells were counted randomly at 200× magnification (.028 mm 2 per field), and the data were averaged. To normalize the data from the 2 institutes, normalized CD8 or CD163 scores were determined using the following formula: {(the number of CD8 or CD163-positive cells) − (average)}/(SD). Based on the score, CD8-positive T-cell infiltration was graded as low or high according to the first quartile of the normalized CD8 score. The average proportions of PD-L1-positive cells were estimated at low magnification and given a percentage score ranging from 0 to 4 (0 = 0%, 1 = 0%-10%, 2 = 10%-20%, 3 = 20%-50% and 4 = 50%-100%). The intensities of positively stained cells were estimated at high magnification and given a score ranging from 0 to 3 (0 = no staining, 1 = weak staining, 2 = intermediate staining and 3 = strong staining). The immunohistochemistry (IHC) scores were then calculated by multiplying the percentage score by the intensity score. To normalize the data from the 2 institutes, normalized IHC scores were determined using the following formula: {(IHC score) − (average)}/(SD). Based on the score, PD-L1 expression was graded as low or high.
| Sourcedata
For the Cancer Genome Atlas (TCGA) analysis, raw RNA-seq data of TCGA samples were downloaded from Genomic Data Commons.
PDCD1 samples were separated into 2 groups by third quartile values. The survival curves for these 2 groups (high, n = 133; low, n = 44) were constructed according to the Kaplan-Meier method, and survival was compared between groups using the log-rank test.
| Doubleimmunostaining
After IHC analysis with the anti-PD-L1 antibody using FFPE sections harvested from PDAC patients as described above, we stained and colored the same sections with an anti-Iba 1 antibody (#019-19741; WAKO, Osaka, Japan) and Histogreen (Linaris, Wertheim, Germany), respectively.
| Celllines
The human PDAC cell lines were purchased from RIKEN Cell Bank (Japan), and DAUDI cells were established from patients with Burkitt lymphoma (RIKEN Cell Bank). All cell lines were maintained in D-MEM or RPMI medium (WAKO) supplemented with 10% FBS (Mediatech, Osaka, Japan).
| Real-timePCR
Total RNA was extracted from cultured cells or human tissues using a RNeasy Mini Kit (QIAGEN, Tokyo, Japan), and reverse transcription and real-time PCR were performed as previously described. 19 The following real-time PCR primers were used:
CD274, 5′-GGCATCCAAGATACAAACTCAA-3′ (forward) and 5′-CAGAAGTTCCAATGCTGGATTA-3′ (reverse);
and 5′-CCCGGTCTGCCAAATAAATAC-3′ (reverse). 
| Macrophagecultures
| Cytokinetreatments
Cytokine treatments were performed as previously described. 
| Flowcytometry
Flow cytometry analysis was performed as previously described. 
| Inhibitionofthenuclearfactor-kappaB signalingpathway
To inhibit the nuclear factor-kappa B (NF-κB) signaling pathway, MIAPaCa2 cells were treated with dehydroxymethylepoxyquinomicin (DHMEQ, 10 ng/mL, COSMO BIO, Japan) for 1 hour. The cells were then treated with TNF-α at 20 ng/mL and an equal concentration of inhibitor for 6 hours for RNA extraction, 24 hours for PD-L1 protein extraction, or 1 hour for NF-κB and phosphorylated NF-κB protein extraction.
| Wholecelllysateextraction
Total protein was extracted using RIPA buffer (Thermo, Tokyo, Japan), and protein concentrations were determined using a BCA Protein Assay Kit (Thermo) according to the manufacturer's instructions.
| Westernblotanalysis
Samples were prepared for western blot analysis by adding 4× SDS-PAGE sample buffer and incubating for 5 minutes at 95°C. Proteins 
| Elisa
Media conditioned with PDAC cells alone, macrophages alone or macrophages treated with 100 ng/mL LPS for 48 hours were collected.
The samples were subjected to ELISA as previously described 19 using a Quantikine ELISA Human TNF-α Immunoassay Kit (R&D Systems, Minneapolis, USA) according to the manufacturer's instructions.
| Immunocytostaining
Macrophages were fixed with 1% paraformaldehyde, and CD163 expression was examined with an anti-CD163 antibody (Clone No.
AM-3K, Transgenic, Japan) as described previously. 
| Statisticalanalysis
Continuous variables are expressed as the means ± SD and were compared using Student's t tests. Categorical variables were compared using χ
-tests. Correlation analysis was performed using
Pearson's product-moment correlation coefficient. All analyses were conducted with JMP 13.2.1 software (SAS, USA), and P-values < .05
were considered significant.
| RE SULTS
| PD-L1expressionissignificantlyassociated withpoorprognosisinpancreaticductal adenocarcinomapatients
The PD-1/PD-L1 interaction has a critical role in the immunotolerance by which cancer cells evade elimination by CD8-positive T cells. To investigate the clinical significance of PD-L1 expression and the number of CD8-positive T cells in PDAC patients, immunohistochemistry analysis of PD-L1 and CD8 was performed on consecutive paraffin sections from 235 PDAC patients. The overall survival in the high PD-L1 expression group was significantly worse than that in the low PD-L1 expression group (5-year survival rate: 7.9% vs 33%, P = .0058, Figure 1A ). The survival data from TCGA samples supported the survival data from our cohort (5-year survival rate: high, .0% vs low, 37.3%, P = .0043, Figure 1B ). In addition, our survival analysis showed that patients with high CD8-positive T-cell infiltration had a better prognosis than those with low CD8-positive T-cell infiltration (5-year survival rate: 34.4% vs 12.5%, P = .0005, Figure 1C ). Following a previous study, 23 enrolled patients were allocated into 4 groups based on PD-L1 expression and the number of infiltrating CD8-positive T cells ( Figure 1D ). Although PD-L1 expression did not have a significant impact on prognosis in PDAC patients F I G U R E 1 PD-L1 expression is significantly associated with poor prognosis in pancreatic ductal adenocarcinoma (PDAC) patients. A, The overall survival of 235 PDAC patients who underwent surgical resection with curative intent according to their level of PD-L1 expression.
Patients in the high PD-L1 expression group had a poorer survival rate than those in the low PD-L1 expression group (5-year survival rate: 6.6% vs 31%, P = .012). B, Kaplan-Meier survival curve using pancreatic cancer TCGA data (n = 177). Higher expression of PD-L1 in pancreatic cancer specimens was associated with poorer survival (5-year survival rate: high, .0% vs low, 37.3%, P = .0043). C, The overall survival of 235 PDAC patients who underwent surgical resection with curative intent according to CD8-positive T-cell infiltration. Patients with high CD8-positive T-cell infiltration had better prognosis than those with low CD8-positive T-cell infiltration (5-year survival rate: 36.1% vs 12.3%, P = .027). D, Enrolled patients were allocated to 4 groups based on PD-L1 expression and the number of infiltrating CD8-positive T cells: high PD-L1 expression and high CD8 T-cell infiltration (Type I), low and low (Type II), high and low (Type III), or low and high (Type IV). E, The overall survival of the same patients according to their types. The Type I group showed the poorest prognosis among all groups. The combination of PD-L1 expression and CD8-positive T-cell infiltrations was correlated with prognosis. F, G, Mortality after patients were subcategorized according to the intensity of CD8-positive T cells. For higher CD8-positive T-cell infiltration, the PD-L1-high expression group showed significantly poorer prognosis than the PD-L1-low expression group (P = .012)
harboring low CD8-positive T-cell infiltration (P = .46, Figure 1G ), PD-L1 expression was significantly associated with poor prognosis in PDAC patients harboring high CD8-positive T-cell infiltration (P = .030, Figure 1F ).
| PD-L1expressioniscorrelatedwithCD163-positivetumor-infiltratingmacrophages
To examine the relationship between PD-L1 expression and tumor- Figure 2C ). Moreover, we examined the survival analysis based on CD163-positive macrophage infiltration. Consistent with the results of a previous study, 24 PDAC patients with high CD163-positive macrophage infiltration tended to have poorer prognosis than those with low CD163-positive macrophage infiltration; however, this difference was not significant in our cohort ( Figure S1 , P = .19).
| PD-L1expressioninpancreaticductal adenocarcinomacellsisenhancedafterco-culture withmacrophagesderivedfromhumanmonocytes
To investigate the molecular mechanism of PD-L1 expression in PDAC cells, we first examined PD-L1 mRNA and protein expression in PDAC cells ( Figures 3A,B and S2 ). Macrophages were differentiated from human monocytes and co-cultured with these PDAC cells. Activated macrophages harboring CD163 produced abundant cytokines ( Figure S3 ) and were also co-cultured with PDAC cells.
PD-L1 mRNA expression was assessed in PDAC cells co-cultured
with macrophages, which revealed upregulated expression in both 
| Tumornecrosisfactor-αstrongly inducesPD-L1expressioninpancreaticductal adenocarcinomacells
The specificity of the anti-PD-L1 antibody was tested using PDAC cell lines ( Figure 4A) . Of the various cytokines tested, TNF-α and IFN-γ strongly induced PD-L1 expression in both S2-013 ( Figure 4B) and MIAPaCa2 cells ( Figure 4C ). In addition, TNF-α promoted PD-L1
protein expression on these cells as determined by flow cytometry analysis ( Figures 4D,E) . The PD-L1 mRNA levels corresponded to PD-L1 expression on the cancer cell membrane.
| MolecularmechanismofPD-L1expressionin pancreaticductaladenocarcinomacells
An inhibitor assay was performed to clarify the molecular mechanism of PD-L1 expression. MIAPaCa2 cells were used for the inhibitor assay because flow cytometry indicated that PD-L1 was expressed at higher levels on MIAPaCa2 cells than on S2-013 cells after TNF-α treatment. PD-L1 mRNA expression was increased after TNF-α was added, and this upregulation was inhibited by the NF-κB inhibitor in MIAPaCa2 cells ( Figure 4F ). These findings suggest that TNF-α can promote PD-L1 expression in PDAC cells via the NF-κB pathway. This result was further supported by the results of western blot analysis, which showed that PD-L1 and phosphorylated NF-κB levels were increased after the addition of TNF-α and that this upregulation was inhibited by the NF-κB inhibitor in MIAPaCa2 cells ( Figures 4G and S4 ).
| CorrelationbetweenPD-L1expressionand tumornecrosisfactor-αmRNAexpressionin cancertissues
Immunohistochemistry analyses and real-time PCR were performed to examine PD-L1 protein expression and TNF-α mRNA levels in the same series of PDAC tissues. A positive correlation was observed ( Figure 4H,I ). Macrophage infiltration around PD-L1-positive PDAC cells was also confirmed using double immunostaining ( Figure 4J ).
| PD-L1expressioninpancreaticductal adenocarcinomacellsisenhancedbymacrophagederivedtumornecrosisfactor-α
ELISA analysis revealed that human monocyte-derived macrophages activated by LPS produced substantial amounts of TNF-α ( Figure 5A ).
The amount of TNF-α was almost identical among all types of macrophages tested ( Figure S3b) . Furthermore, the upregulation of PD-L1 after co-culture with macrophages was inhibited by an anti-TNF-α antibody ( Figure 5B ). This result was further supported by the results of western blot analysis ( Figures 5C and S5 ). These findings suggest that PD-L1 expression in PDAC cells is upregulated by macrophage-derived TNF-α. cancer, [27] [28] [29] and are known to have abundant clinical benefits. In addition, our survival analysis revealed that PD-L1-high patients with PDAC had poorer prognoses than PD-L1-low patients, supporting previous findings that patients harboring PD-L1-positive tumor cells had significantly poorer prognoses than those harboring PD-L1-negative tumor cells in several types of cancer, 30, 31 including pancreatic cancer. 15, 16 The infiltration rate of CD8-positive T cells has been reported to be correlated with better prognosis. [32] [33] [34] [35] [36] Similarly, our survival analysis showed that patients with high CD8-positive T-cell infiltration had a better prognosis than those with low The plus sign indicates that the inhibitor was added, whereas the minus sign indicates that the inhibitor was not added. PD-L1 expression was increased in MIAPaCa2 cells after treatment with TNF-α and was inhibited after treatment with both TNF-α and NF-κB inhibitors. G, Western blot analysis of proteins detected by probing with anti-NF-κB or anti-phosphorylated NF-κB antibodies. TNF-α increased the level of phosphorylated NF-κB. Full-length gels are presented in Figure S4 . H, Correlation between PD-L1 expression and TNF-α mRNA levels in frozen human PDAC tissues. Patients were sorted into a high or low PD-L1 expression group based on analysis of frozen tissues, and the (H) PD-L1 expression in paraffin sections and TNF-α mRNA expression in frozen tissues harvested from the same PDAC patients (I) were compared. PD-L1 expression was typically high in patients with high TNF-α mRNA levels. Macrophage infiltration was also confirmed in consecutive paraffin sections using double immunostaining with PD-L1 and Iba-1 antibodies (J). The cells stained brown represent PD-L1-expressing PDAC cells, whereas those stained green are infiltrating macrophages Notably, we found that CD163-positive macrophage infiltration was significantly associated with PD-L1 expression in PDAC cells in consecutive paraffin sections harvested from PDAC patients, supporting observations in other types of cancer. 17, 18 Consistent with this finding, PD-L1 expression was upregulated in PDAC cells co-cultured with activated macrophages derived from human monocytes. Macrophages are known to produce various cytokines, including TNF-α, IL-1 and IL-6, and among these cytokines, we determined that TNF-α enhanced PD-L1 expression in PDAC cells. Moreover, the upregulation of PD-L1 after co-culture with macrophages was inhibited by an anti-TNF-α antibody.
| D ISCUSS I ON
These results suggest that PD-L1 expression in PDAC cells is upregulated by macrophage-derived TNF-α in the tumor microenvironment. Macrophages also produce low levels of IFN-γ under LPS-stimulation, 37 and it has been suggested that in addition to TNF-α, macrophage-derived IFN-γ enhanced PD-L1 expression in PDAC cells. Thus, the current study identified another potential mechanism underlying PD-L1 expression: production of TNF-α by activated macrophages and subsequent promotion of PD-L1 expression by TNF-α via NF-κB signaling in PDAC cells.
In conclusion, PD-L1 expression in PDAC cells is promoted by TNF-α derived from tumor-infiltrating macrophages, potentially F I G U R E 5 A, The concentration of tumor necrosis factor (TNF)-α in each conditioned medium determined by ELISA. Macrophages treated with lipopolysaccharide (LPS) produced substantial amounts of TNF-α. B, Human monocyte-derived macrophages were co-cultured with S2-013 or MIAPaCa2 cells. An anti-TNF-α antibody was then used at 1 μg/mL to neutralize TNF-α produced by macrophages treated with 100 ng/mL LPS for 24 h. PD-L1 mRNA expression in S2-013 and MIAPaCa2 cells was upregulated after co-culture with activated macrophages; this upregulation was inhibited by treatment with 1 μg/mL anti-TNF-α antibody. The plus symbol indicates that the antibody was added, and the minus symbol indicates that the antibody was not added. C, Western blot analysis of proteins detected by probing with anti-PD-L1 antibodies. PD-L1 expression upregulated by co-culture with activated macrophages was inhibited by an anti-TNF-α antibody. Full-length gels are presented in Figure S5 leading to a poor prognosis for patients with PDAC. These findings suggest the possibility of inhibiting aberrant PD-L1 induction by blocking with an anti-TNF-α antibody.
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